EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin

Teck-Phui Chua, Jose L Huaman, Jennifer Danielewski, Catriona S Bradshaw, Dorothy A Machalek, Michael J McDonald, Suzanne M Garland, Gerald L Murray iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Teck-Phui Chua und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Fluoroquinolones, Mycoplasma genitalium, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Research Council Industrial Transformation Research Hub for Antimicrobial Resistance, NHMRC Investigator Grant, Australian Government Research Training Program Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current knowledge of Mycoplasma genitalium fluoroquinolone resistance is based on sequence analyses of clinical samples, an approach with limited scope. Many potential resistance mutations have been described but their impact on moxifloxacin efficacy is unclear.

Objective

To investigate the impact of individual mutations on fluoroquinolone resistance through selection of moxifloxacin-resistant mutants in vitro.

Methods

M. genitalium G37 was passaged sequentially in sub-inhibitory concentrations of moxifloxacin. MIC values were determined for moxifloxacin, sitafloxacin, levofloxacin and ciprofloxacin. Bacterial populations were profiled using amplicon sequencing.

Results

Across three independent experiments, four moxifloxacin mutants were isolated, with mutations encoding the following protein sequence variations: (i) GyrA D99Y/ParE E468K, (ii) ParC S83I/GyrA D99Y/ParE E468K, (iii) ParC D87V/GyrB P462S and (iv) GyrA M95I/ParE E468dup. Moxifloxacin MICs were elevated 16- to 32-fold for mutants with a single GyrA or ParC variation, and 128-fold for the dual GyrA/ParC mutant. Sitafloxacin MICs were elevated but remained lower than moxifloxacin MICs. Mutations did not have a substantial impact on in vitro growth dynamics. Population analysis showed that multiple mutations attained detectable population-wide frequencies, with evidence of clonal interference dynamics, with a minority becoming fixed in the population.

Conclusion

Mutations in multiple genes conferring fluoroquinolone resistance appeared with regularity in vitro. Findings of an additive effect for ParC/GyrA changes, and greater effectiveness of sitafloxacin against resistant bacteria compared with moxifloxacin, are both consistent with clinical data. Improved understanding of fluoroquinolone resistance will inform the development of diagnostic assays predicting fluoroquinolone susceptibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesMycoplasma genitaliumAnti-Bacterial AgentsDrug Resistance, BacterialEvolution, MolecularMoxifloxacinMicrobial Sensitivity TestsHumansDNA GyraseDNA Topoisomerase IVMutationSerial PassageSelection, Genetic

Substanzen

MoxifloxacinFluoroquinolonesAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IV

Autor:innen und Institutionen

  • Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Parkville, Victoria, Australia.
  • Centre for Women's Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.
  • Molecular Microbiology Research Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria, Australia.
  • School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Gerald L Murray

Förderung

  • Australian Research Council Industrial Transformation Research Hub for Antimicrobial Resistance
  • NHMRC Investigator Grant
  • Australian Government Research Training Program Scholarship

Zitieren

APA

Chua, T. P., Huaman, J. L., Danielewski, J., Bradshaw, C. S., Machalek, D. A., McDonald, M. J., Garland, S. M., & Murray, G. L. (2025). In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf324

Vancouver

Chua TP, Huaman JL, Danielewski J, Bradshaw CS, Machalek DA, McDonald MJ, et al. In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf324

BibTeX
@article{Chua2025,
  author = {Chua, Teck-Phui and Huaman, Jose L and Danielewski, Jennifer and Bradshaw, Catriona S and Machalek, Dorothy A and McDonald, Michael J and Garland, Suzanne M and Murray, Gerald L},
  title = {In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf324}
}
Kostenlos starten →